Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Group 1 - Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system disorders [2] - The company plans to host a conference call and webcast on March 19, 2026, at 4:30 PM ET to discuss its financial results for the fourth quarter ended December 31, 2025, and recent business progress [1] - The lead candidates of the company, NDV-01 and sepranolone, are advancing through mid-stage clinical development, addressing significant unmet needs in their respective fields [2] Group 2 - A replay of the webcast will be available in the Investors section of the Relmada website [1] - Contact information for investor inquiries is provided, with Brian Ritchie from LifeSci Advisors as the point of contact [2] - Media inquiries can be directed to the corporate communications team via the provided email [3]